Adelaide Research & Scholarship: Search

Search

Results 1-10 of 44 (Search time: 0.005 seconds).

previous
1
2
3
4
...
5
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2004	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity	Coller, J.; Krebsfaenger, N.; Klein, K.; Wolbold, R.; Nussler, A.; Neuhaus, P.; Zanger, U.; Eichelbaum, M.; Murdter, T.
	2003	Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.	Sallustio, B.; Davies, B.; Coller, J.; James, H.; Gillis, D.; Somogyi, A.
	2010	The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation	Helsby, N.; Hui, C.; Goldthorpe, M.; Coller, J.; Soh, M.; Gow, P.; de Zoysa, J.; Tingle, M.
	2009	Role of active metabolites in the use of opioids	Coller, J.; Christrup, L.; Somogyi, A.
	2007	Pharmacogenetics of opioids	Somogyi, A.; Barratt, D.; Coller, J.
	2007	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia	Inglis, S.; Herbert, M.; Davies, B.; Coller, J.; James, H.; Horowitz, J.; Morris, R.; Milne, R.; Somogyi, A.; Sallustio, B.
	2007	CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes	Davies, B.; Coller, J.; Somogyi, A.; Milne, R.; Sallustio, B.
	2007	Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon	Coller, J.; Joergensen, C.; Foster, D.; James, H.; Gillis, D.; Christrup, L.; Somogyi, A.
	2012	Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients	Coller, J.; Michalakas, J.; James, H.; Farquharson, A.; Colvill, J.; White, J.; Somogyi, A.
	2012	ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics	Barratt, D.; Coller, J.; Hallinan, R.; Byrne, A.; White, J.; Foster, D.; Somogyi, A.